Isracann Bioscience Inc. (ISCNF)

[pual]

I suggest that ISCNF (IPOT) has now become a great opportunity for large gains (pps a CDN$ 0,10 or US$ 0,08).

For almost all of 2021 the only news we got allowing to think that the company wasn’t dead were that, Isracann appointed a new Experienced Farm Manager (August) and a new CEO (October).

This week we find that: ‘Isracann has determined to return to a normalized business, focusing on:
- transition from development to operations at the Ein Hahoresh facility,
- differentiation, solid partnership strategies as well as immediate options to revenue,
- understanding how best to maximize operations in the near future and
- generating revenue and shareholder value in 2022.’

The new CEO said : ‘We don’t see any significant regulatory hurdles other than awaiting the final go-ahead from a government, believing the approvals are imminent’

The market cap of the company is still less than CDN $15m or US $12m and it looks (from more recent balance sheet) that debt is still relatively minimal(?).

By the way, according to MORNINGSTAR, fair value of the stock is already CDN $0,18 or US $0,145.

I plan to sit on my xxx,xxx shares, notwithstanding my high avg costs (CDN $0,195)